Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) and Possible Other Treatments in Adolescent and Adult Males With Fragile X Syndrome (FXS)

NCT04823052 is registered in ClinicalTrials.gov with Healx Limited as lead sponsor.

NCT NCT04823052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04823052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) and Possible Other Treatments in Adolescent and Adult Males With Fragile X Syndrome (FXS)
Lead sponsor
Healx Limited
Phase
Phase 2
Overall status
Withdrawn
Start date
May 25, 2022
Completion date
October 19, 2022
Enrollment
0 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome